Bone Health News and Research

RSS

$Researchers identify 32 genetic regions associated with osteoporosis, fracture$

Researchers identify 32 genetic regions associated with osteoporosis, fracture

Thirty-two previously unidentified genetic regions associated with osteoporosis and fracture have been identified by a large, worldwide consortium of researchers, including Stanford Prevention Research Center chief John Ioannidis, MD, DSc. Variations in the DNA sequences in these regions confer either risk or protection from the bone-weakening disease. Many, but not all, of the regions encode proteins involved in pathways known to involve bone health.

16 Apr 2012

Study reveals genetic predictors of bone health and osteoporosis

An international consortium of researchers have identified a group of genes associated with the development of osteoporosis, a debilitating bone disease that cripples more than 10 million Americans a year and costs the U.S. healthcare system an estimated $17 billion annually.

16 Apr 2012

More than 60% of breast cancer survivors report post-treatment complications

More than 60 percent of breast cancer survivors report at least one treatment-related complication even six years after their diagnosis, according to a new study led by a researcher from the Perelman School of Medicine at the University of Pennsylvania.

10 Apr 2012

Financial incentives for purchasing a healthier food option

The aging baby boomers and subsequent generations will be looking to the food industry to provide products that can help them live longer, healthier and more active lives than previous generations, according to research presented at the Institute of Food Technologists' Wellness 12 meeting.

5 Apr 2012

ECTS, IOF publish guidance document to manage GIO

Oral glucocorticoids are commonly prescribed for a wide variety of disorders, most commonly for rheumatoid arthritis, obstructive pulmonary disease and inflammatory bowel diseases. However, the use of these medications can result in rapid bone loss during the first three to six months of therapy, leading to increased risk of fragility fractures.

28 Mar 2012

Specific precautions must be taken for individuals on longer-term oral glucocorticoid therapy

Millions of people around the world are prescribed glucocorticoids for a wide variety of inflammatory conditions, including, rheumatoid arthritis, asthma and inflammatory bowel diseases. Although they are effective and widely used, one of the potentially serious side effects of these medications is glucocorticoid-induced osteoporosis.

28 Mar 2012

UK researcher receives IOF-Servier Young Investigator Research Grant

The IOF-Servier Young Investigator Research Grant has been awarded to Dr Mark Edwards, clinical research fellow at the MRC Lifecourse Epidemiology Unit at Southhampton General Hospital in the UK.

27 Mar 2012

Combination of everolimus and exemestane reduces spread of cancer in the bone

Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.

23 Mar 2012

Highlights from Journal of the American Academy of Orthopaedic Surgeons

The Spine Patient Outcomes Research Trial (SPORT) is the first comprehensive study to look at the effectiveness of different treatments for low back and leg pain. It was designed to provide data and outcomes to guide doctors and their patients in their treatment choices for three common spinal disorders: intervertebral disk herniation (IDH), degenerative spondylolisthesis (DS), and lumbar spinal stenosis (LSS).

14 Mar 2012

$Vitamin D may reduce risk of stress fracture in girls$

Vitamin D may reduce risk of stress fracture in girls

Vitamin D may be associated with a lower risk of developing stress fractures in preadolescent and adolescent girls, especially among those very active in high-impact activities, according to a report published Online First by Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

6 Mar 2012

$Vitamin D in pre-teen girls protects from stress fractures and bone injuries: Study$

Vitamin D in pre-teen girls protects from stress fractures and bone injuries: Study

A new study shows that girls and young women who got lots of vitamin D through their diet and supplements were half as likely to suffer a stress fracture as those who didn't.

5 Mar 2012

Vitamin E may lead to thinning and weakening of bones: Study

From studies in laboratory animals it was found that the most common form of vitamin E stimulates the generation of bone-degrading cells. Scientists who carried out the research in Japan are now calling for their results to be followed up in humans.

4 Mar 2012

Scientists identify specific mechanisms by which vitamin D inhibits inflammation

Researchers at National Jewish Health have discovered specific molecular and signaling events by which vitamin D inhibits inflammation. In their experiments, they showed that low levels of Vitamin D, comparable to levels found in millions of people, failed to inhibit the inflammatory cascade, while levels considered adequate did inhibit inflammatory signaling.

24 Feb 2012

Pediatricians should screen all children for vitamin D deficiency

As study after study shows the fundamental role vitamin D plays in disease and health, vitamin D deficiency — which often develops insidiously in childhood — should be on every parent's and pediatrician's radar, say physicians from the Johns Hopkins Children's Center.

23 Feb 2012

People with celiac disease are at risk for osteoporosis

People with celiac disease are at risk for osteoporosis, according to physicians at Loyola University Health System (LUHS). A 2009 New England Journal of Medicine study supports this correlation. Researchers believe that people with celiac disease may develop osteoporosis because their body poorly absorbs calcium and vitamin D, which are necessary for bone health.

22 Feb 2012

FDA prioritizes review of Ra-223 and MDV3100 for treating CRPC

The arsenal of prostate cancer treatments for men with advanced prostate cancer may soon be strengthened as the FDA prioritizes the review of both Ra-223 and MDV3100 for treating metastatic castration-resistant prostate cancer (CRPC). Based on positive, independent research of each drug, better survival rates and improved bone health for patients with late-stage prostate cancer may be within reach.

18 Feb 2012

Paricalcitol does not improve clinical outcomes for patients with CKD

Patients with chronic kidney disease who received the vitamin D compound paricalcitol for up to 48 weeks did not show improvement on measures of cardiac structure, function, or left ventricular mass, compared to patients who received placebo, according to a study in the February 15 issue of JAMA.

15 Feb 2012